Human Papillomavirus T-Cell Cross-reactivity in Cervical Cancer: Implications for Immunotherapy Clinical Trial Design

IMPORTANCE: Clinical trials are testing vaccines that target human papillomavirus 16 (HPV-16) oncoproteins for the treatment of cervical cancer regardless of the HPV type of the tumor. For patients with HPV-18–positive cancers, this strategy relies on cross-reactivity of HPV-16–reactive T cells agai...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Netw Open
Päätekijät: Helman, Sarah R., Stevanović, Sanja, Campbell, Tracy E., Kwong, Mei Li M., Doran, Stacey L., Faquin, William C., Hinrichs, Christian S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2018
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324313/
https://ncbi.nlm.nih.gov/pubmed/30646017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2018.0706
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia